220 related articles for article (PubMed ID: 16611154)
1. Migraine: current therapeutic targets and future avenues.
Arulmozhi DK; Veeranjaneyulu A; Bodhankar SL
Curr Vasc Pharmacol; 2006 Apr; 4(2):117-28. PubMed ID: 16611154
[TBL] [Abstract][Full Text] [Related]
2. Migraine: current concepts and emerging therapies.
Arulmozhi DK; Veeranjaneyulu A; Bodhankar SL
Vascul Pharmacol; 2005 Sep; 43(3):176-87. PubMed ID: 16099727
[TBL] [Abstract][Full Text] [Related]
3. Current and prospective pharmacological targets in relation to antimigraine action.
Mehrotra S; Gupta S; Chan KY; Villalón CM; Centurión D; Saxena PR; MaassenVanDenBrink A
Naunyn Schmiedebergs Arch Pharmacol; 2008 Oct; 378(4):371-94. PubMed ID: 18626630
[TBL] [Abstract][Full Text] [Related]
4. Serotonin in migraine: theories, animal models and emerging therapies.
Johnson KW; Phebus LA; Cohen ML
Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
[TBL] [Abstract][Full Text] [Related]
5. Developments in 5-hydroxytryptamine receptor pharmacology in migraine.
Peroutka SJ
Neurol Clin; 1990 Nov; 8(4):829-39. PubMed ID: 2259314
[TBL] [Abstract][Full Text] [Related]
6. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
Gupta S; Villalón CM
Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
Blumenfeld A; Gennings C; Cady R
Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
De Vries P; Villalón CM; Saxena PR
Eur J Pharmacol; 1999 Jun; 375(1-3):61-74. PubMed ID: 10443565
[TBL] [Abstract][Full Text] [Related]
9. Migraine: pathophysiology, pharmacology, treatment and future trends.
Villalón CM; Centurión D; Valdivia LF; de Vries P; Saxena PR
Curr Vasc Pharmacol; 2003 Mar; 1(1):71-84. PubMed ID: 15320857
[TBL] [Abstract][Full Text] [Related]
10. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments.
Villalón CM; VanDenBrink AM
Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216
[TBL] [Abstract][Full Text] [Related]
11. Practical considerations for the treatment of elderly patients with migraine.
Sarchielli P; Mancini ML; Calabresi P
Drugs Aging; 2006; 23(6):461-89. PubMed ID: 16872231
[TBL] [Abstract][Full Text] [Related]
12. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A
Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
[TBL] [Abstract][Full Text] [Related]
14. The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
Hamel E
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S2-6. PubMed ID: 10563226
[TBL] [Abstract][Full Text] [Related]
15. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy.
Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR
Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581
[TBL] [Abstract][Full Text] [Related]
16. Is the 5-HT(7) receptor involved in the pathogenesis and prophylactic treatment of migraine?
Terrón JA
Eur J Pharmacol; 2002 Mar; 439(1-3):1-11. PubMed ID: 11937086
[TBL] [Abstract][Full Text] [Related]
17. Side effects associated with current and prospective antimigraine pharmacotherapies.
González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
[TBL] [Abstract][Full Text] [Related]
18. New migraine and pain research.
Hargreaves R
Headache; 2007 Apr; 47 Suppl 1():S26-43. PubMed ID: 17425708
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications.
Slassi A
Curr Top Med Chem; 2002 Jun; 2(6):559-74. PubMed ID: 12052194
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in migraine.
Solomon GD
J Clin Pharmacol; 1993 Mar; 33(3):200-9. PubMed ID: 8385160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
